Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152033 | 0.85 | ALDH1A1 (0.40) | NOS3NOS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6152446 | 0.85 | NOS3 (0.35) | NOS3NOS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6152508 | 0.82 | NOS3 (0.36) | NOS3NOS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6152633 | 0.82 | NOS3 (0.33) | NOS3NOS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6152064 | 0.82 | SMN1; SMN2 (0.39) | NOS3NOS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6152460 | 0.80 | NOS3 (0.33) | NOS3NOS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6152284 | 0.80 | PHGDH (0.31) | NOS3NOS2PHGDH | |
| SCHEMBL6153509 | 0.78 | PHGDH (0.38) | NOS3NOS2SMN1; SMN2KMT2APHGDH | |
| SCHEMBL6152619 | 0.78 | PHGDH (0.40) | KMT2APHGDHLMNA | |
| SCHEMBL6153002 | 0.78 | PDE2A (0.36) | NOS3NOS2SMN1; SMN2LCKPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943181-B2 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2005-09-13 | — | — | US | claimed |
| EP-1406610-B1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-01-26 | — | — | EP | claimed |
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2004-09-09 | — | — | US | claimed |
| EP-1406610-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004016-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| US-6943181-B2 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2005-09-13 | — | — | US | disclosed |
| EP-1551832-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-1406610-B1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004031185-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| EP-1406610-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004016-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | BACE1, MYC, APP | NOS3 1914/4885NOS2 1714/4885NPC1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.